Hans Schikan is a co-founder of Pharvaris. He is former CEO of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases including Duchenne muscular dystrophy. Prosensa was listed on NASDAQ in 2013 and acquired by BioMarin in 2015.
Hans was previously at Genzyme, latest as VP for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. He is currently Chairman of the Board of Complix and InteRNA, Board Member of Sobi, Vicore Pharma and VectivBio.
He is also member of the Top Team of the Dutch Top Sector Life Sciences & Health. Previously, he served on the boards of Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion) and Therachon (acquired by Pfizer).
He has a Pharm.D. degree from Utrecht University.